RenovoRx Return On Equity vs. Total Debt
| RNXT Stock | USD 0.95 0.01 1.06% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 3.07 | Current Value 3.22 | Quarterly Volatility 1.34915069 |
For RenovoRx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of RenovoRx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well RenovoRx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between RenovoRx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of RenovoRx over time as well as its relative position and ranking within its peers.
RenovoRx |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RenovoRx. If investors know RenovoRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RenovoRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of RenovoRx is measured differently than its book value, which is the value of RenovoRx that is recorded on the company's balance sheet. Investors also form their own opinion of RenovoRx's value that differs from its market value or its book value, called intrinsic value, which is RenovoRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RenovoRx's market value can be influenced by many factors that don't directly affect RenovoRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RenovoRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if RenovoRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RenovoRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
RenovoRx Total Debt vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining RenovoRx's current stock value. Our valuation model uses many indicators to compare RenovoRx value to that of its competitors to determine the firm's financial worth. RenovoRx is rated below average in return on equity category among its peers. It is rated below average in total debt category among its peers . At this time, RenovoRx's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value RenovoRx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.RenovoRx Total Debt vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
RenovoRx |
| = | -2.59 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
RenovoRx |
| = | 4.47 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
RenovoRx Total Debt vs Competition
RenovoRx is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 64.63 Million. RenovoRx holds roughly 4.47 Million in total debt claiming about 7% of equities under Health Care industry.
RenovoRx Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in RenovoRx, profitability is also one of the essential criteria for including it into their portfolios because, without profit, RenovoRx will eventually generate negative long term returns. The profitability progress is the general direction of RenovoRx's change in net profit over the period of time. It can combine multiple indicators of RenovoRx, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 3.5 M | 3.6 M | |
| Net Interest Income | 127.7 K | 134 K | |
| Interest Income | 127.7 K | 64.3 K | |
| Operating Income | -10.3 M | -10.8 M | |
| Net Loss | -8.2 M | -8.7 M | |
| Income Before Tax | -9.2 M | -9.7 M | |
| Total Other Income Expense Net | 1.3 M | 1.4 M | |
| Net Loss | -8.9 M | -9.3 M | |
| Net Loss | -9.2 M | -9.7 M | |
| Income Tax Expense | (5.40) | (5.13) | |
| Change To Netincome | -29.7 K | -28.2 K | |
| Net Loss | (1.14) | (1.20) | |
| Income Quality | 0.90 | 0.74 | |
| Net Income Per E B T | 1.14 | 1.17 |
RenovoRx Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on RenovoRx. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of RenovoRx position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the RenovoRx's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in RenovoRx without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Use Investing Themes to Complement your RenovoRx position
In addition to having RenovoRx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold and Gold Mining Thematic Idea Now
Gold and Gold Mining
Large and mid-size companies, ETFs and funds that are either investing, exploring or producing, gold or indirectly involved in trading or making gold products. The Gold and Gold Mining theme has 73 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold and Gold Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.